Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GLOBAL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY CLINICAL ASSAYS

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PK ASSAYS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. TIERED IMMUNOGENICITY TESTING

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. NAB ASSAYS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 GLOBAL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY COMPARABILITY TESTING

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. EFFECTOR BINDING BIACORE

5.2.1. FcγRI (CD64)
5.2.2. FcγRII (CD32a)
5.2.3. FcγRIII (CD16a)
5.2.4. FcRn
5.2.5. Market size and forecast

5.3. C1Q BINDING BY ELISA

5.3.1. Market size and forecast

5.4. KINETIC BINDING ASSAYS BY BIACORE

5.4.1. Market size and forecast

5.5. ADCC AND CDC ASSAYS CELL BASED ASSAYS

5.5.1. Market size and forecast

Chapter: 6 GLOBAL BIOSIMILAR TESTING AND DEVELOPMENT SERVICES MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Global Biosimilar Testing and Development Services Market, by Clinical Assays
6.2.5. North America Global Biosimilar Testing and Development Services Market, by Comparability Testing

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Global Biosimilar Testing and Development Services Market, by Clinical assays
6.3.5. Europe Global Biosimilar Testing and Development Services Market, by Comparability Testing

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Global Biosimilar Testing and Development Services Market, by Clinical Assays
6.4.5. Asia-Pacific Global Biosimilar Testing and Development Services Market, by Comparability Testing

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast

6.5.4. LAMEA Global Biosimilar Testing and Development Services Market, by Clinical Assays
6.5.5. LAMEA Global Biosimilar Testing and Development Services Market, by Comparability Testing

Chapter: 7 COMPANY PROFILES

7.1. EUROFINS SCIENTIFIC

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. SGS SA

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. CHARLES RIVER LABORATORIES INTERNATIONAL INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. EXOVA GROUP PLC.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. SOURCE BIOSCIENCE PLC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. INTERTEK GROUP PLC.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MEDISTRI SA

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. PACE ANALYTICAL SERVICES INC.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. SIGMA-ALDRICH CO. LLC

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments